$CRL
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$CRL
Charles River Laboratories
$CRLNYSEHealthcareMid-Cap
Charles River provides drug discovery and development services including preclinical and clinical laboratory services.
Market Cap
$10.0B
Revenue (TTM)
$4.0B
-3.0%
Net Income (TTM)
$0.3B
-10.0%
EPS (TTM)
$5.50
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$155-$275
Beta
1.15
Dimension Scores
Fundamental
56Technical
56Sentiment
60Risk / Reward
62Momentum
50Financial Health
Profitability
61moderate
Growth
53weak
Liquidity
70strong
Solvency
58moderate
Efficiency
54moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $CRL
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.